Loading stock data…
Natera, Inc. (NTRA)
$324.14-4.04 (-1.23%)
Market ClosedLast close Sep 8
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Natera, Inc. in the Healthcare sector is trading at $324.14 with a market capitalization of $44.7B. Wall Street consensus targets $338.07 (21 analysts), implying a +4.3% move over the next 12 months. The stock is currently near its 52-week high of $343.18, remaining 37.2% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $752.75M↑ | $696.64M↑ | $665.50M↑ | $592.18M↑ | $546.60M |
| Gross Profit | $485.19M↑ | $450.83M↑ | $445.43M↑ | $384.38M↑ | $346.60M |
| Operating Income | -$75.79M↑ | -$93.52M↓ | -$22.79M↑ | -$97.58M↑ | -$110.37M |
| Net Income | -$66.97M↑ | -$85.09M↓ | $47.26M↑ | -$87.54M↑ | -$100.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$44.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.51
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.56%
Volume
Today's trading volume
1.03M
Recent News
3 Momentum Stocks to Own for Decades
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
The billionaire has good reasons to like this genetic testing leader.
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
3 Healthcare Stocks with Promising Prospects
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% gain over the past six months, beating the S&P 500 by 13.3 percentage points.
How Investors May Respond To Natera (NTRA) New MRD Trial Deal And Duquesne Stake Expansion
Natera recently announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers, expanding the use of its technology in oncology research. At the same time, Duquesne Family Office significantly increased its position in Natera, making the diagnostics company its largest healthcare holding and underscoring rising institutional interest in its MRD and medtech platform. Now we’ll explore how this...